Salvatore Perrone

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 22

Top Venues

Cancers

Annals of hematology

Expert review of hematology

Nuclear medicine and molecular imaging

This page only lists publications with an associated author ORCID identifier.

Publications

Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. Annals of hematology (2023)
Pierantonio Menna, Francesco Marchesi, Chiara Cattaneo, Anna Candoni, Mario Delia, Gianpaolo Nadali, Alessandra Vatteroni, Crescenza Pasciolla, Salvatore Perrone, Luisa Verga, Daniele Armiento, Maria Ilaria Del Principe, Nicola S Fracchiolla, Emanuela Salvatorelli, Santina Lupisella, Irene Terrenato, Alessandro Busca, Giorgio Minotti, Livio Pagano
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study. Clinical and translational science (2023)
Matteo Molica, Salvatore Perrone, Marco Rossi
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 -Mutated AML Patients. Journal of clinical medicine 12 (11) (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
Salvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, Ilenia Iamundo De Cumis, Alessandro Pulsoni, Paolo Strati
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond. Cancers 15 (10) (2023)
Matteo Molica, Salvatore Perrone, Vincenzo Federico, Caterina Alati, Stefano Molica, Marco Rossi
Venetoclax: A Game Changer in the Treatment of Younger AML Patients? Cancers 16 (1) (2023)
Matteo Molica, Salvatore Perrone, Costanza Andriola, Marco Rossi
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. Cancers 15 (20) (2023)
Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. Annals of hematology 102 (4) (2023)
Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. Annals of hematology 102 (4) (2023)
Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. Annals of hematology 102 (4) (2023)
Salvatore Perrone, Saveria Capria, Massimo Bernardi, Francesco Marchesi, Elettra Ortu La Barbera, Silvia Maria Trisolini, Clara Minotti, Mahnaz Shafii Bafti, Maria Cristina Scerpa, Antonino Mulé, Fabio Ciceri, Maurizio Martelli, Giuseppe Cimino
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients. Annals of hematology 102 (4) (2023)
Matteo Molica, Salvatore Perrone, Carla Mazzone, Laura Cesini, Martina Canichella, Paolo de Fabritiis
CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML. Cancers 14 (12) (2022)
Salvatore Perrone, Paolo Lopedote, Mario Levis, Alice Di Rocco, Stephen Douglas Smith
Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. Expert review of hematology 15 (3) (2022)
Matteo Molica, Carla Mazzone, Pasquale Niscola, Ida Carmosino, Ambra Di Veroli, Cinzia De Gregoris, Fabrizio Bonanni, Salvatore Perrone, Natalia Cenfra, Luana Fianchi, Anna Lina Piccioni, Antonio Spadea, Giovanni Luzi, Andrea Mengarelli, Laura Cudillo, Luca Maurillo, Livio Pagano, Massimo Breccia, Luigi Rigacci, Paolo De Fabritiis
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience. Cancers 14 (19) (2022)
Matteo Molica, Salvatore Perrone
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours. Expert review of hematology 15 (11) (2022)
Matteo Molica, Salvatore Perrone, Carla Mazzone, Pasquale Niscola, Laura Cesini, Elisabetta Abruzzese, Paolo de Fabritiis
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers 13 (13) (2021)
Salvatore Perrone, Natalia Cenfra, Federica Viola, Anna Carraro, Raffaella Marocco, Miriam Lichtner, Giuseppe Cimino
Unexpected cause of pancytopenia in a teenager with Noonan syndrome. EJHaem 2 (3) (2021)
Salvatore Perrone, Mauro Passucci, Elettra Ortu La Barbera, Marcello Capriata, Antonietta Ferretti, Alessandra Mecozzi, Piera Giovangrossi, Francesco Equitani, Giuseppe Cimino
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura. Journal of clinical apheresis 36 (3) (2021)
Serena Rosati, Carmelo Gurnari, Massimo Breccia, Ida Carmosino, Emilia Scalzulli, Enrico Montefusco, Salvatore Perrone, Ombretta Annibali, Vincenza Martini, Giulio Trapè, Gioia Colafigli, Malgorzata Trawinska, Clara Minotti, Giuseppe Cimino, Agostino Tafuri, Giuseppe Avvisati, Maurizio Martelli, Maria Teresa Voso, Roberto Latagliata
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta oncologica (Stockholm, Sweden) 60 (11) (2021)
Giovanni Manfredi Assanto, Costantino Riemma, Francesco Malaspina, Salvatore Perrone, Maria L De Luca, Alessandra Pucciarini, Giorgia Annechini, Gianna M D'Elia, Maurizio Martelli, Caterina Ilari, Enrico Tiacci, Alessandro Pulsoni
The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. British journal of haematology 194 (1) (2021)
Salvatore Perrone, Elettra Ortu La Barbera, Tiziana Ottone, Marcello Capriata, Mauro Passucci, Luca Filippi, Oreste Bagni, Maria Teresa Voso, Giuseppe Cimino
Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. Nuclear medicine and molecular imaging 54 (5) (2020)
Andrés José Maria Ferreri, Teresa Calimeri, Gian Marco Conte, Dario Cattaneo, Federico Fallanca, Maurilio Ponzoni, Eloise Scarano, Flavio Curnis, Alessandro Nonis, Paolo Lopedote, Giovanni Citterio, Letterio Salvatore Politi, Marco Foppoli, Stefania Girlanda, Marianna Sassone, Salvatore Perrone, Caterina Cecchetti, Fabio Ciceri, Claudio Bordignon, Angelo Corti, Nicoletta Anzalone
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. Blood 134 (3) (2019)

Salvatore Perrone.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Salvatore Perrone